Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTAWNKZ)

DTT Name	Norepinephrine transporter (NET)
Synonyms	Solute carrier family 6 member 2; Sodium-dependent noradrenaline transporter; SLC6A2; NET1; NET; NAT1
Gene Name	SLC6A2
DTT Type	Successful target	[1]
BioChemical Class	Neurotransmitter:sodium symporter
UniProt ID	SC6A2_HUMAN
TTD ID	T21945
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Sequence	MLLARMNPQVQPENNGADTGPEQPLRARKTAELLVVKERNGVQCLLAPRDGDAQPRETWG KKIDFLLSVVGFAVDLANVWRFPYLCYKNGGGAFLIPYTLFLIIAGMPLFYMELALGQYN REGAATVWKICPFFKGVGYAVILIALYVGFYYNVIIAWSLYYLFSSFTLNLPWTDCGHTW NSPNCTDPKLLNGSVLGNHTKYSKYKFTPAAEFYERGVLHLHESSGIHDIGLPQWQLLLC LMVVVIVLYFSLWKGVKTSGKVVWITATLPYFVLFVLLVHGVTLPGASNGINAYLHIDFY RLKEATVWIDAATQIFFSLGAGFGVLIAFASYNKFDNNCYRDALLTSSINCITSFVSGFA IFSILGYMAHEHKVNIEDVATEGAGLVFILYPEAISTLSGSTFWAVVFFVMLLALGLDSS MGGMEAVITGLADDFQVLKRHRKLFTFGVTFSTFLLALFCITKGGIYVLTLLDTFAAGTS ILFAVLMEAIGVSWFYGVDRFSNDIQQMMGFRPGLYWRLCWKFVSPAFLLFVVVVSIINF KPLTYDDYIFPPWANWVGWGIALSSMVLVPIYVIYKFLSTQGSLWERLAYGITPENEHHL VAQRDIRQFQLQHWLAI
Function	Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
KEGG Pathway	Synaptic vesicle cycle (hsa04721 )
Reactome Pathway	Na+/Cl- dependent neurotransmitter transporters (R-HSA-442660 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This DTT

28 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[2]
Amfepramone	DM9YSNQ	Migraine	8A80	Approved	[3]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[4]
Amoxapine	DMKITQE	Major depressive disorder	6A70.3	Approved	[5]
Atomoxetine	DM5L6HI	Attention deficit hyperactivity disorder	6A05.Z	Approved	[6]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[1]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[7]
Dasotraline	DMLDQFV	Attention deficit hyperactivity disorder	6A05.Z	Approved	[8]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[2]
Desvenalfaxine succinate	DMJE6KO	Fibromyalgia	MG30.01	Approved	[9]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[10]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[11]
Iobenguane I-123	DM80OEZ	Neuroendocrine cancer	2B72.1	Approved	[12]
Levomilnacipran	DMV26S8	Fibromyalgia	MG30.01	Approved	[13]
Maprotiline	DMPWB7T	Depression	6A70-6A7Z	Approved	[14]
Mazindol	DMZ36RN	Obesity	5B81	Approved	[15]
Milnacipran	DMBFE74	Depression	6A70-6A7Z	Approved	[16]
Netarsudil	DM0LPI9	Open-angle glaucoma	9C61	Approved	[17]
Phenmetrazine	DMXYTN9	Obesity	5B81	Approved	[18]
Phentermine	DMG60XN	Obesity	5B81	Approved	[19]
Protriptyline	DMNHTZI	Depression	6A70-6A7Z	Approved	[20]
Reboxetine	DM26PRD	Depression	6A70-6A7Z	Approved	[21]
Sibutramine	DMFJTDI	Obesity	5B81	Approved	[22]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[23]
Trimipramine	DM1SC8M	Major depressive disorder	6A70.3	Approved	[24]
Venlafaxine	DMR6QH0	Anxiety disorder	6B00-6B0Z	Approved	[1]
Hypericum	DM8NWFD	N. A.	N. A.	Phase 4	[25]
SPN-812	DMTV7XH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[26]
------------------------------------------------------------------------------------


⏷ Show the Full List of 28 Approved Drug(s)

15 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amitifadine	DMS1X67	Obesity	5B81	Phase 3	[12]
Bicifadine	DM42GP9	Chronic low back pain	MG30.02	Phase 3	[27]
Roclatan	DMVQ5X1	Glaucoma/ocular hypertension	9C61	Phase 3	[28]
Suronacrine maleate	DMH2FN1	Cognitive impairment	6D71	Phase 3	[29]
18F-LMI-1195	DM8JVIB	Heart failure	BD10-BD13	Phase 2	[30]
BLI-1005	DMYK1DR	Major depressive disorder	6A70.3	Phase 2	[26]
MCT-125	DMDR2SZ	Fatigue	MG22	Phase 2	[12]
Metaiodobenzylguanidine I-131	DMNST69	Neuroblastoma	2D11.2	Phase 2	[31]
NS 2359	DMI5HFU	Cocaine addiction	6C45.2	Phase 2	[32]
PDC-1421	DMGP9VN	Attention deficit hyperactivity disorder	6A05.Z	Phase 2	[33]
Spiroglumide	DM7NJWY	Stomach disease	DA43-DA4Y	Phase 2	[34]
TD-9855	DMQD5NA	Pain	MG30-MG3Z	Phase 2	[35]
XEN-2174	DM0NFMS	Cancer related pain	MG30	Phase 2	[36]
BL-1021	DMAYSFK	Pain	MG30-MG3Z	Phase 1	[37]
GSK-1360707	DMZC9XU	Major depressive disorder	6A70.3	Phase 1	[38]
------------------------------------------------------------------------------------


⏷ Show the Full List of 15 Clinical Trial Drug(s)

10 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DOV-216303	DMTE14H	Mood disorder	6A60-6E23	Discontinued in Phase 2	[32]
Esreboxetine	DMTUHWM	Fibromyalgia	MG30.01	Discontinued in Phase 2	[39]
Manifaxine	DMRN7GC	Major depressive disorder	6A70.3	Discontinued in Phase 2	[40]
Napitane mesilate	DMF9Y57	Major depressive disorder	6A70.3	Discontinued in Phase 2	[41]
NS-2389	DMVRJ8D	Major depressive disorder	6A70.3	Discontinued in Phase 2	[42]
R-sibutramine metabolite	DMPAH74	Attention deficit hyperactivity disorder	6A05.Z	Discontinued in Phase 2	[43]
Radafaxine	DMARQE0	Major depressive disorder	6A70.3	Discontinued in Phase 2	[44]
SPD-473	DMTJNRL	Mood disorder	6A60-6E23	Discontinued in Phase 2	[45]
NSD-644	DMNL9DS	Neurological disorder	6B60	Discontinued in Phase 1	[46]
RG-7166	DMKLPMW	Major depressive disorder	6A70.3	Discontinued in Phase 1	[47]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Discontinued Drug(s)

173 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
((3R,4R)-4-(o-tolyloxy)chroman-3-yl)methanamine	DM2TIU3	Discovery agent	N.A.	Investigative	[48]
(+/-)-3-((naphthalen-2-yloxy)methyl)pyrrolidine	DML68KX	Discovery agent	N.A.	Investigative	[49]
(2S,3S)-2-(m-Tolyl)-3,5,5-trimethylmorpholin-2-ol	DMDUI8R	Discovery agent	N.A.	Investigative	[50]
(2S,3S)-2-Phenyl-3,5,5-trimethylmorpholin-2-ol	DMDUGZS	Discovery agent	N.A.	Investigative	[50]
(R)-1-((S)-morpholin-2-yl)-1,2-diphenylethanol	DMBXRKS	Discovery agent	N.A.	Investigative	[51]
(R)-2-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol	DM74IWX	Discovery agent	N.A.	Investigative	[52]
(R)-3-(naphthalen-2-ylmethoxy)pyrrolidine	DM94B12	Discovery agent	N.A.	Investigative	[49]
(R)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile	DM134UV	Discovery agent	N.A.	Investigative	[49]
(R)-DULOXETINE	DMECK7H	Discovery agent	N.A.	Investigative	[53]
(R)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide	DMJFH97	Discovery agent	N.A.	Investigative	[54]
(R)-N-isopropyl-N-(pyrrolidin-3-yl)-2-naphthamide	DMQIUOB	Discovery agent	N.A.	Investigative	[54]
(R)-Norfluoxetine	DMS30KU	Discovery agent	N.A.	Investigative	[55]
(S)-3-(naphthalen-2-ylmethoxy)pyrrolidine	DM5ILK1	Discovery agent	N.A.	Investigative	[49]
(S)-6-(pyrrolidin-3-ylmethoxy)-2-naphthonitrile	DM32PJ5	Discovery agent	N.A.	Investigative	[49]
(S)-N-isobutyl-N-(pyrrolidin-3-yl)-2-naphthamide	DMUAYZJ	Discovery agent	N.A.	Investigative	[54]
(S)-NORDULOXETINE	DMULFYA	Discovery agent	N.A.	Investigative	[53]
(S)-Norfluoxetine	DM8ZTPF	Discovery agent	N.A.	Investigative	[55]
1-(1,2-diphenylethyl)piperazine	DM0ARKB	Discovery agent	N.A.	Investigative	[56]
1-(1,4-diphenylbutan-2-yl)piperazine	DM8Z1QU	Discovery agent	N.A.	Investigative	[57]
1-(1-(2-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)	DMCSOAV	Discovery agent	N.A.	Investigative	[52]
1-(1-(4-FLUOROPHENYL)-2-(2-(TRIFLUOROMETHOXY)PHENYL)ETHYL)PIPERAZINE (ENANTIOMERIC MIX)	DMS9PZ7	Discovery agent	N.A.	Investigative	[52]
1-(1-phenyl-2-(2-propoxyphenyl)ethyl)piperazine	DM54ZKU	Discovery agent	N.A.	Investigative	[52]
1-(1-phenyl-2-o-tolylethyl)piperazine	DMZ6QX0	Discovery agent	N.A.	Investigative	[56]
1-(2,3-Dihydro-1H-indol-5-ylmethyl)-propylamine	DM0URSE	Discovery agent	N.A.	Investigative	[58]
1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine	DMJXKOF	Discovery agent	N.A.	Investigative	[59]
1-(2-(2-(DIFLUOROMETHOXY)PHENYL)-1-PHENYLETHYL)PIPERAZINE (ENANTIOMERIC MIX)	DMUJ2WB	Discovery agent	N.A.	Investigative	[52]
1-(2-(2-bromophenyl)-1-phenylethyl)piperazine	DMPRALC	Discovery agent	N.A.	Investigative	[56]
1-(2-(2-chlorophenoxy)pyridin-3-yl)piperazine	DM9CVX5	Discovery agent	N.A.	Investigative	[60]
1-(2-(2-chlorophenyl)-1-phenylethyl)piperazine	DMUM4YQ	Discovery agent	N.A.	Investigative	[56]
1-(2-(2-ethoxyphenyl)-1-phenylethyl)piperazine	DMBRS3D	Discovery agent	N.A.	Investigative	[56]
1-(2-(2-ethylphenyl)-1-phenylethyl)piperazine	DMKWRCD	Discovery agent	N.A.	Investigative	[56]
1-(2-(2-fluorobenzyloxy)phenyl)piperazine	DM6XCPV	Discovery agent	N.A.	Investigative	[59]
1-(2-(2-methoxyphenyl)-1-phenylethyl)piperazine	DM2H38V	Discovery agent	N.A.	Investigative	[52]
1-(2-(3-chlorophenyl)-1-phenylethyl)piperazine	DM4WEGM	Discovery agent	N.A.	Investigative	[56]
1-(2-(3-fluorophenoxy)phenyl)piperazine	DMXV2KQ	Discovery agent	N.A.	Investigative	[59]
1-(2-(3-methoxyphenyl)-1-phenylethyl)piperazine	DM8V5IH	Discovery agent	N.A.	Investigative	[56]
1-(2-(4-fluorophenoxy)phenyl)piperazine	DMU082P	Discovery agent	N.A.	Investigative	[59]
1-(2-(6-fluoronaphthalen-2-yl)ethyl)piperazine	DMR4DJ1	Discovery agent	N.A.	Investigative	[49]
1-(2-(benzyloxy)phenyl)piperazine	DM0UZHL	Discovery agent	N.A.	Investigative	[59]
1-(2-(phenoxymethyl)phenyl)piperazine	DM7Z19T	Discovery agent	N.A.	Investigative	[59]
1-(2-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one	DMBWCOZ	Discovery agent	N.A.	Investigative	[61]
1-(2-phenoxyphenyl)piperazine	DMWFCYN	Discovery agent	N.A.	Investigative	[59]
1-(3,4-Dichloro-phenyl)-3-diethylamino-indan-5-ol	DMN4JU0	Discovery agent	N.A.	Investigative	[62]
1-(3,4-Dichloro-phenyl)-3-methylamino-indan-5-ol	DMWIEDN	Discovery agent	N.A.	Investigative	[62]
1-(3-bromophenyl)-2-(tert-butylamino)propan-1-one	DM2SEXH	Discovery agent	N.A.	Investigative	[63]
1-(3-chlorophenyl)-2-(dimethylamino)propan-1-one	DMFYJ5V	Discovery agent	N.A.	Investigative	[63]
1-(3-chlorophenyl)-2-(piperidin-1-yl)propan-1-one	DMPOVUY	Discovery agent	N.A.	Investigative	[63]
1-(3-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one	DMPEZ1V	Discovery agent	N.A.	Investigative	[61]
1-(3-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one	DMB9T6F	Discovery agent	N.A.	Investigative	[61]
1-(4-bromophenyl)-2-(tert-butylamino)propan-1-one	DMW6YDK	Discovery agent	N.A.	Investigative	[63]
1-(4-bromophenyl)-2-pyrrolidin-1-yl-pentan-1-one	DMPLEC0	Discovery agent	N.A.	Investigative	[61]
1-(4-fluorophenyl)-2-pyrrolidin-1-yl-pentan-1-one	DM6ARQF	Discovery agent	N.A.	Investigative	[61]
1-(4-iodophenyl)-2-pyrrolidin-1-yl-pentan-1-one	DMBV8PT	Discovery agent	N.A.	Investigative	[61]
1-(4-nitrophenyl)-2-pyrrolidin-1-yl-pentan-1-one	DME435S	Discovery agent	N.A.	Investigative	[61]
1-naphthalen-2-yl-2-pyrrolidin-1-yl-pentan-1-one	DMU04ZQ	Discovery agent	N.A.	Investigative	[61]
1S,2R-milnacipran	DM7Y5AN	Discovery agent	N.A.	Investigative	[64]
2-((2-iodophenoxy)(phenyl)methyl)morpholine	DMS1AOK	Discovery agent	N.A.	Investigative	[65]
2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine	DMS21CR	Discovery agent	N.A.	Investigative	[65]
2-(2'-Aminoethyl)-5-benzyltetrahydrofuran	DMVTD1F	Discovery agent	N.A.	Investigative	[66]
2-(2,3-Dihydro-1H-indol-5-yl)-1-methyl-ethylamine	DM56NK4	Discovery agent	N.A.	Investigative	[58]
2-(2-chlorophenoxy)-3-(piperidin-4-yl)pyridine	DM1ULEX	Discovery agent	N.A.	Investigative	[60]
2-(2-fluorophenoxy)-3-(piperidin-4-yl)pyridine	DM1SN37	Discovery agent	N.A.	Investigative	[60]
2-(2-methoxyphenoxy)-3-(piperidin-4-yl)pyridine	DMYVDJQ	Discovery agent	N.A.	Investigative	[60]
2-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile	DMO9SP1	Discovery agent	N.A.	Investigative	[56]
2-(Aminomethyl)-5-(1'-naphthethyl)tetrahydrofuran	DMU4MIC	Discovery agent	N.A.	Investigative	[66]
2-(Aminomethyl)-5-(1'-naphthyl)tetrahydrofuran	DMCUTY9	Discovery agent	N.A.	Investigative	[66]
2-(Aminomethyl)-5-(2'-naphthyl)tetrahydrofuran	DM157SO	Discovery agent	N.A.	Investigative	[66]
2-(Aminomethyl)-5-phenethyltetrahydrofuran	DMEZ7O2	Discovery agent	N.A.	Investigative	[66]
2-(N,N-Diethylamino)-3'-chloropropiophenone	DMVR248	Discovery agent	N.A.	Investigative	[67]
2-(N-Cyclopentylamino)-3'-bromopropiophenone	DML4GHA	Discovery agent	N.A.	Investigative	[63]
2-(N-Cyclopentylamino)-3'-chloropropiophenone	DMP68CE	Discovery agent	N.A.	Investigative	[67]
2-(N-Cyclopentylamino)-3'-fluoropropiophenone	DMH6FKX	Discovery agent	N.A.	Investigative	[63]
2-(N-Cyclopentylamino)-3'-methoxypropiophenone	DMVN1UI	Discovery agent	N.A.	Investigative	[63]
2-(N-Cyclopentylamino)-3'-methylpropiophenone	DMG87RK	Discovery agent	N.A.	Investigative	[63]
2-(N-Cyclopropylamino)-3-chloropropiophenone	DMNMES3	Discovery agent	N.A.	Investigative	[67]
2-(N-Pyrrolidinyl)-3'-bromopropiophenone	DM85ZCW	Discovery agent	N.A.	Investigative	[63]
2-(N-Pyrrolidinyl)-3'-fluoropropiophenone	DMYPOC5	Discovery agent	N.A.	Investigative	[63]
2-(N-Pyrrolidinyl)-3'-methoxypropiophenone	DM1W3L9	Discovery agent	N.A.	Investigative	[63]
2-(N-Pyrrolidinyl)-3'-methylpropiophenone	DMGKXOI	Discovery agent	N.A.	Investigative	[63]
2-(N-Pyrrolidinyl)-3'-nitropropiophenone	DM1I9LQ	Discovery agent	N.A.	Investigative	[63]
2-(N-tert-Butylamino)-3',4'-dichloropropiophenone	DMKIEVP	Discovery agent	N.A.	Investigative	[67]
2-(N-tert-Butylamino)-3'-chloroheptanophenone	DMY2PBO	Discovery agent	N.A.	Investigative	[67]
2-(N-tert-Butylamino)-3'-chlorohexanophenone	DMPO3CJ	Discovery agent	N.A.	Investigative	[67]
2-(N-tert-Butylamino)-3'-chlorooctanophenone	DMW47VA	Discovery agent	N.A.	Investigative	[67]
2-(N-tert-Butylamino)-3'-chloropentanophenone	DMTZ540	Discovery agent	N.A.	Investigative	[67]
2-(N-tert-Butylamino)propiophenone	DM9E5LT	Discovery agent	N.A.	Investigative	[67]
2-(tert-butylamino)-1-(3-chlorophenyl)butan-1-one	DMI457Y	Discovery agent	N.A.	Investigative	[63]
2-(tert-butylamino)-1-m-tolylpropan-1-one	DM6PV4W	Discovery agent	N.A.	Investigative	[63]
2-(tert-butylamino)-1-p-tolylpropan-1-one	DMYFQDT	Discovery agent	N.A.	Investigative	[63]
2-(tert-Butylamino)-3',4'-dichlorobutyrophenone	DMOJK8Y	Discovery agent	N.A.	Investigative	[67]
2-(tert-Butylamino)-3',4'-dichloropentanophenone	DMMUDQ7	Discovery agent	N.A.	Investigative	[67]
2-Amino-1-(4-methylthiophenyl)propane	DMJ2Z9G	Discovery agent	N.A.	Investigative	[68]
2-Aminomethyl-5-(p-bromophenyl)tetrahydrofuran	DMCJUWK	Discovery agent	N.A.	Investigative	[66]
2-Aminomethyl-5-(p-chlorophenyl)tetrahydrofuran	DM3OTZY	Discovery agent	N.A.	Investigative	[66]
2-Aminomethyl-5-(p-methoxyphenyl)tetrahydrofuran	DMDG8FL	Discovery agent	N.A.	Investigative	[66]
2-Aminomethyl-5-(p-t-butylphenyl)tetrahydrofuran	DME4P7K	Discovery agent	N.A.	Investigative	[66]
2-Aminomethyl-5-(phenyl)tetrahydrofuran	DM413ZB	Discovery agent	N.A.	Investigative	[66]
2-phenoxy-3-(piperidin-4-yl)pyridine	DM6JNT5	Discovery agent	N.A.	Investigative	[60]
2pyrrolidin-1-yl-1-phenylpentan-1-one	DMBJXCF	Discovery agent	N.A.	Investigative	[61]
3-(1H-indol-1-yl)-N-methyl-3-phenylpropan-1-amine	DMLV80B	Discovery agent	N.A.	Investigative	[69]
3-(2-phenyl-2-(piperazin-1-yl)ethyl)benzonitrile	DM6YJOU	Discovery agent	N.A.	Investigative	[56]
3-(2-phenyl-2-(piperazin-1-yl)ethyl)phenol	DM6QZTB	Discovery agent	N.A.	Investigative	[56]
3-(3'-furyl)-aniline	DM7FQVC	Discovery agent	N.A.	Investigative	[70]
3-(piperidin-4-yl)-2-(o-tolyloxy)pyridine	DM2ETXB	Discovery agent	N.A.	Investigative	[60]
3-p-Tolyl-8-aza-bicyclo[3.2.1]octane	DM0872E	Discovery agent	N.A.	Investigative	[71]
3alpha-(bis-chloro-phenylmethoxy)tropane	DMBUZWQ	Discovery agent	N.A.	Investigative	[72]
4-((naphthalen-2-yloxy)methyl)piperidine	DMIQHYZ	Discovery agent	N.A.	Investigative	[49]
4-(1H-indol-3-yl)-N,N-dimethylcyclohex-3-enamine	DM7Y1ZD	Discovery agent	N.A.	Investigative	[73]
4-(2-((3-fluorophenoxy)methyl)phenyl)piperidine	DMJ9CNA	Discovery agent	N.A.	Investigative	[59]
4-(2-(2-fluoro-5-methylphenoxy)phenyl)piperidine	DM9UA0N	Discovery agent	N.A.	Investigative	[59]
4-(2-(2-fluorobenzyloxy)phenyl)piperidine	DMCR3VM	Discovery agent	N.A.	Investigative	[59]
4-(2-(3-chlorophenoxy)phenyl)piperidine	DM0IT5E	Discovery agent	N.A.	Investigative	[59]
4-(2-(3-fluorophenoxy)-4-methylphenyl)piperidine	DMEPB9L	Discovery agent	N.A.	Investigative	[59]
4-(2-(3-fluorophenoxy)phenyl)piperidine	DMZMEOG	Discovery agent	N.A.	Investigative	[59]
4-(2-(4-fluorobenzyloxy)phenyl)piperidine	DM29QLG	Discovery agent	N.A.	Investigative	[59]
4-(2-(4-fluorophenoxy)-4-methylphenyl)piperidine	DMJNB8C	Discovery agent	N.A.	Investigative	[59]
4-(2-(4-fluorophenoxy)phenyl)piperidine	DMFQT9O	Discovery agent	N.A.	Investigative	[59]
4-(2-(benzyloxy)-3-fluorophenyl)piperidine	DMM2NHZ	Discovery agent	N.A.	Investigative	[59]
4-(2-(benzyloxy)-6-fluorophenyl)piperidine	DMF3S50	Discovery agent	N.A.	Investigative	[59]
4-(2-(benzyloxy)phenyl)piperidine	DMOC7PY	Discovery agent	N.A.	Investigative	[59]
4-(2-(phenoxymethyl)phenyl)piperidine	DM0OFRQ	Discovery agent	N.A.	Investigative	[59]
4-(2-fluoro-6-(2-fluorophenoxy)phenyl)piperidine	DMQUAP2	Discovery agent	N.A.	Investigative	[60]
4-(2-fluoro-6-(3-fluorophenoxy)phenyl)piperidine	DMUBHRF	Discovery agent	N.A.	Investigative	[59]
4-(2-fluoro-6-(4-fluorophenoxy)phenyl)piperidine	DMJ2GW0	Discovery agent	N.A.	Investigative	[59]
4-(2-fluoro-6-phenoxyphenyl)piperidine	DMXIGWC	Discovery agent	N.A.	Investigative	[59]
4-(2-phenoxyphenyl)piperidine	DMB5IFA	Discovery agent	N.A.	Investigative	[59]
4-(3'-furyl)-aniline	DMZ1TNM	Discovery agent	N.A.	Investigative	[70]
4-(3-fluoro-2-phenoxyphenyl)piperidine	DM1C3NZ	Discovery agent	N.A.	Investigative	[59]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[74]
6-(piperidin-4-ylmethoxy)-2-naphthonitrile	DMBQKGY	Discovery agent	N.A.	Investigative	[49]
7-(piperidin-4-ylmethoxy)-2-naphthonitrile	DM6I5K1	Discovery agent	N.A.	Investigative	[49]
8-Methyl-3-p-tolyl-8-aza-bicyclo[3.2.1]octane	DMOM4VS	Discovery agent	N.A.	Investigative	[71]
AMIFLAMINE	DMJ0BEG	Discovery agent	N.A.	Investigative	[58]
Biphenyl-2-ylmethyl-(S)-pyrrolidin-3-yl-amine	DM4D7V6	Discovery agent	N.A.	Investigative	[75]
Cis-3-phenoxy-2,3-dihydro-1H-inden-1-amine	DMTH4BG	Discovery agent	N.A.	Investigative	[76]
D-166A	DMQJD4P	Discovery agent	N.A.	Investigative	[77]
D-211A	DMIBOAK	Discovery agent	N.A.	Investigative	[77]
D-211B	DM54CKZ	Discovery agent	N.A.	Investigative	[77]
D-254C	DM6KFCO	Discovery agent	N.A.	Investigative	[77]
D-257A	DMN7E6Y	Discovery agent	N.A.	Investigative	[77]
D-257C	DM5GLJ2	Discovery agent	N.A.	Investigative	[77]
Difluorobenztropine	DM8ABD6	Discovery agent	N.A.	Investigative	[72]
Isobutyl-(4-methyl-benzyl)-piperidin-4-yl-amine	DM293XH	Discovery agent	N.A.	Investigative	[78]
KF-A5	DMFBMYG	Discovery agent	N.A.	Investigative	[79]
MDL-28618	DMF76M8	Discovery agent	N.A.	Investigative	[48]
METHYLENEDIOXYAMPHETAMINE	DMP204G	Discovery agent	N.A.	Investigative	[80]
METHYLENEDIOXYMETHAMPHETAMINE	DMYVU47	Discovery agent	N.A.	Investigative	[81]
MMDA	DMUWVGP	Discovery agent	N.A.	Investigative	[82]
N,N-dimethyl(2-phenoxyphenyl)methanamine	DMWK91T	Discovery agent	N.A.	Investigative	[83]
N-(2-oxazolemethyl)milnacipran	DMVGP02	Discovery agent	N.A.	Investigative	[84]
N-benzyl-N-isobutylpiperidin-4-amine	DM6QK7E	Discovery agent	N.A.	Investigative	[78]
N-desalkylquetiapine	DMBFC1U	Discovery agent	N.A.	Investigative	[85]
NISOXETINE	DMZBNH0	Discovery agent	N.A.	Investigative	[86]
norzotepine	DMS3N4X	Discovery agent	N.A.	Investigative	[87]
Para-chloroamphetamine	DMOH75D	Discovery agent	N.A.	Investigative	[68]
PF-18298	DMJMU09	Discovery agent	N.A.	Investigative	[52]
PF-3409409	DMEZA0T	Attention deficit hyperactivity disorder	6A05.Z	Investigative	[88]
PF-526014	DMD8QOZ	Discovery agent	N.A.	Investigative	[52]
POLYGALATENOSIDE B	DMUTV5P	Discovery agent	N.A.	Investigative	[89]
PTI-601	DMQUSXK	Pain	MG30-MG3Z	Investigative	[12]
PYROVALERONE	DMV48S2	Discovery agent	N.A.	Investigative	[61]
R-NORDULOXETINE	DMGV4DS	Discovery agent	N.A.	Investigative	[53]
RTI-219	DM2QYXN	Discovery agent	N.A.	Investigative	[90]
S-34324	DMZLQ5W	Discovery agent	N.A.	Investigative	[91]
S33005	DM3Z6TI	Depression	6A70-6A7Z	Investigative	[92]
TQ-1017	DMEF32D	Pain	MG30-MG3Z	Investigative	[93]
Trans-3-(o-tolyloxy)-2,3-dihydro-1H-inden-1-amine	DMEDC5I	Discovery agent	N.A.	Investigative	[76]
WAY-256805	DM48MC3	Pain	MG30-MG3Z	Investigative	[94]
WIN-35066-2	DMOX1S0	N. A.	N. A.	Investigative	[95]
[3-(3,4-Dichloro-phenyl)-indan-1-yl]-methyl-amine	DM4BYEQ	Discovery agent	N.A.	Investigative	[62]
[3H]nisoxetine	DMS3WNG	Discovery agent	N.A.	Investigative	[12]
[3H]WIN35428	DMI8RU0	Discovery agent	N.A.	Investigative	[96]
{2-[3-(Phenylsulfonyl)-1H-indol-4-yl]ethyl}amine	DM3FBAZ	Discovery agent	N.A.	Investigative	[97]
------------------------------------------------------------------------------------


⏷ Show the Full List of 173 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Major depressive disorder	6A20	Pre-frontal cortex	7.05E-01	7.02E-03	0.07
------------------------------------------------------------------------------------

The Drug Transporter (DTP) Role of This DTT

DTT DTP Name

Sodium-dependent noradrenaline transporter (SLC6A2) DTP Info

Gene Name

SLC6A2

2 Approved Drug(s) Transported by This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amphetamine	DMSZQAK	Attention deficit hyperactivity disorder	6A05.Z	Approved	[98]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[99]
------------------------------------------------------------------------------------

References

1	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
2	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
3	Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
4	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
5	Effects of acute and chronic treatment with amoxapine and cericlamine on the sleep-wakefulness cycle in the rat. Neuropharmacology. 1994 Aug;33(8):1017-25.
6	Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl). 2008 Sep;200(1):39-50.
7	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
8	Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults. Neuropsychopharmacology. 2015 Nov;40(12):2745-52.
9	Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
10	Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
11	Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
12	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 926).
13	Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
14	Effect of pharmacologically selective antidepressants on serotonin uptake in rat platelets. Gen Physiol Biophys. 2005 Mar;24(1):113-28.
15	Binding of [3H]mazindol to cardiac norepinephrine transporters: kinetic and equilibrium studies. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jul;370(1):9-16.
16	Milnacipran: beyond a role of antidepressant. Clin Neuropharmacol. 2009 Nov-Dec;32(6):355-63.
17	Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-4.
18	Interaction of the anorectic medication, phendimetrazine, and its metabolites with monoamine transporters in rat brain. Eur J Pharmacol. 2002 Jun 28;447(1):51-7.
19	Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
20	Analgesic properties of intrathecally administered heterocyclic antidepressants. Pain. 1987 Mar;28(3):343-55.
21	Reboxetine: the first selective noradrenaline re-uptake inhibitor. Expert Opin Pharmacother. 2000 May;1(4):771-82.
22	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
23	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
24	Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
25	The experimental and clinical pharmacology of St John's Wort (Hypericum perforatum L.). Mol Psychiatry. 1999 Jul;4(4):333-8.
26	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
27	Preclinical Evaluation of the Abuse Potential of the Analgesic Bicifadine
28	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
29	Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7.
30	Assessment of the 18F-labeled PET tracer LMI1195 for imaging norepinephrine handling in rat hearts. J Nucl Med. 2013 Jul;54(7):1142-6.
31	Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res. 2014 Apr 15;20(8):2182-91.
32	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
33	Clinical pipeline report, company report or official report of BioInvent.
34	Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.
35	Preclinical to clinical translation of CNS transporter occupancy of TD-9855, a novel norepinephrine and serotonin reuptake inhibitor. Int J Neuropsychopharmacol. 2014 Dec 13;18(2). pii: pyu027.
36	Spinal noradrenaline transporter inhibition by reboxetine and Xen2174 reduces tactile hypersensitivity after surgery in rats. Pain. 2005 Feb;113(3):271-6.
37	Company report (BioLineRx)
38	Monoamine transporter occupancy of a novel triple reuptake inhibitor in baboons and humans using positron emission tomography. J Pharmacol Exp Ther. 2013 Aug;346(2):311-7.
39	Pfizer. Product Development Pipeline. March 31 2009.
40	Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects. Pharmacogenet Genomics. 2005 Dec;15(12):883-9.
41	Enhancing central noradrenergic function in depression: is there still a place for a new antidepressant
42	Clinical pipeline report, company report or official report of Neurosearch.
43	Monoamine reuptake site occupancy of sibutramine: Relationship to antidepressant-like and thermogenic effects in rats.Eur J Pharmacol.2014 Aug 15;737:47-56.
44	Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34.
45	Dopamine uptake inhibitor-induced rotation in 6-hydroxydopamine-lesioned rats involves both D1 and D2 receptors but is modulated through 5-hydroxyt... J Pharmacol Exp Ther. 2005 Mar;312(3):1124-31.
46	Clinical pipeline report, company report or official report of Neurosearch.
47	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031598)
48	Synthesis and structure-activity relationships of selective norepinephrine reuptake inhibitors (sNRI) with a heterocyclic ring constraint. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4495-8.
49	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
50	Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48.
51	Discovery of novel and selective tertiary alcohol containing inhibitors of the norepinephrine transporter. Bioorg Med Chem Lett. 2006 Apr 1;16(7):2022-5.
52	Second generation N-(1,2-diphenylethyl)piperazines as dual serotonin and noradrenaline reuptake inhibitors: improving metabolic stability and reduc... Bioorg Med Chem Lett. 2010 Jun 15;20(12):3788-92.
53	Inhibition of serotonin and norepinephrine reuptake and inhibition of phosphodiesterase by multi-target inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Oct 1;17(19):6890-7.
54	Bioorg Med Chem Lett. 2009 Oct 15;19(20):5893-7. Epub 2009 Aug 21.Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
55	Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression. Bioorg Med Chem. 2009 Jan 1;17(1):337-43.
56	N-(1,2-diphenylethyl)piperazines: a new class of dual serotonin/noradrenaline reuptake inhibitor. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4345-8.
57	Structure-activity relationships of N-substituted piperazine amine reuptake inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4349-53.
58	Selective monoamine oxidase inhibitors. 3. Cyclic compounds related to 4-aminophenethylamine. Preparation and neuron-selective action of some 5-(2-... J Med Chem. 1986 Aug;29(8):1406-12.
59	Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1... Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7.
60	Design, synthesis, and pharmacological evaluation of phenoxy pyridyl derivatives as dual norepinephrine reuptake inhibitors and 5-HT1A partial agon... Bioorg Med Chem Lett. 2010 Feb 1;20(3):1114-7.
61	1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem. 2006 Feb 23;49(4):1420-32.
62	Synthesis and pharmacological evaluation of 3-(3,4-dichlorophenyl)-1-indanamine derivatives as nonselective ligands for biogenic amine transporters. J Med Chem. 2004 May 6;47(10):2624-34.
63	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation. J Med Chem. 2010 Mar 11;53(5):2204-14.
64	Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropath... J Med Chem. 2008 Nov 27;51(22):7265-72.
65	Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER. Bioorg Med Chem Lett. 2007 Jan 15;17(2):533-7.
66	2,5-Disubstituted tetrahydrofurans as selective serotonin re-uptake inhibitors. Bioorg Med Chem. 2009 Mar 1;17(5):2047-68.
67	Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem. 2009 Nov 12;52(21):6768-81.
68	Synthesis and serotonin transporter activity of sulphur-substituted alpha-alkyl phenethylamines as a new class of anticancer agents. Eur J Med Chem. 2009 Dec;44(12):4862-88.
69	Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6067-70.
70	Designing active template molecules by combining computational de novo design and human chemist's expertise. J Med Chem. 2007 Apr 19;50(8):1925-32.
71	3alpha-(4-Substituted phenyl)nortropane-2beta-carboxylic acid methyl esters show selective binding at the norepinephrine transporter. Bioorg Med Chem Lett. 2000 Nov 6;10(21):2445-7.
72	Structure-activity relationship studies on a novel series of (S)-2beta-substituted 3alpha-[bis(4-fluoro- or 4-chlorophenyl)methoxy]tropane analogue... J Med Chem. 2006 Oct 19;49(21):6391-9.
73	Conformationally restricted homotryptamines 3. Indole tetrahydropyridines and cyclohexenylamines as selective serotonin reuptake inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3099-104.
74	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
75	Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modu... Bioorg Med Chem Lett. 2008 Aug 1;18(15):4355-9.
76	Discovery of a potent, selective, and less flexible selective norepinephrine reuptake inhibitor (sNRI). Bioorg Med Chem Lett. 2008 Jul 15;18(14):4224-7.
77	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an ex... Bioorg Med Chem. 2008 Mar 15;16(6):2769-78.
78	N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake. Bioorg Med Chem Lett. 2006 May 15;16(10):2714-8.
79	Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob Agents Chemother. 2007 Nov;51(11):4133-40.
80	Synthesis and in vitro toxicity of 4-MTA, its characteristic clandestine synthesis byproducts and related sulfur substituted alpha-alkylthioampheta... Bioorg Med Chem. 2010 Jun 1;18(11):4009-31.
81	The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents. Addiction. 2006 Sep;101(9):1241-5.
82	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
83	1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity. Bioorg Med Chem Lett. 2008 Jan 15;18(2):596-9.
84	Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. Bioorg Med Chem Lett. 2008 Feb 15;18(4):1346-9.
85	N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant ... Neuropsychopharmacology. 2008 Sep;33(10):2303-12.
86	Synthesis and activity of 1-(3-amino-1-phenylpropyl)indolin-2-ones: a new class of selective norepinephrine reuptake inhibitors. Bioorg Med Chem Lett. 2008 Sep 15;18(18):4929-31.
87	Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther. 2010 Jun;333(3):772-81.
88	Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more po... Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83.
89	Antidepressant principles of the roots of Polygala tenuifolia. J Nat Prod. 2006 Sep;69(9):1305-9.
90	Synthesis, monoamine transporter binding, properties, and functional monoamine uptake activity of 3beta-[4-methylphenyl and 4-chlorophenyl]-2 beta-... J Med Chem. 2007 Jul 26;50(15):3686-95.
91	Discovery of a new series of centrally active tricyclic isoxazoles combining serotonin (5-HT) reuptake inhibition with alpha2-adrenoceptor blocking... J Med Chem. 2005 Mar 24;48(6):2054-71.
92	Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century--a medicinal chemistry survey. Curr Top Med Chem. 2006;6(17):1801-23.
93	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
94	Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors. J Med Chem. 2008 Jul 10;51(13):4038-49.
95	Monoamine transporter binding, locomotor activity, and drug discrimination properties of 3-(4-substituted-phenyl)tropane-2-carboxylic acid methyl e... J Med Chem. 2004 Dec 2;47(25):6401-9.
96	3 alpha-(4'-substituted phenyl)tropane-2 beta-carboxylic acid methyl esters: novel ligands with high affinity and selectivity at the dopamine trans... J Med Chem. 1996 Oct 11;39(21):4139-41.
97	Dual acting norepinephrine reuptake inhibitors and 5-HT(2A) receptor antagonists: Identification, synthesis and activity of novel 4-aminoethyl-3-(p... Bioorg Med Chem. 2009 Nov 15;17(22):7802-15.
98	Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci. 2015 Jan;36(1):41-50.
99	Chronic depolarization stimulates norepinephrine transporter expression via catecholamines. J Neurochem. 2006 May;97(4):1044-51.